BETH FITZGERALD: Open Payments
NPI 1053836957 · TAUNTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$915 in 41 payments from 9 companies in 2025. Trend: 2023 $451 · 2024 $470 · 2025 $915
Food & beverage: $915
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 8 | $253 |
| Alkermes, Inc. | 12 | $197 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $143 |
| Neurocrine BioSciences, Inc. | 5 | $104 |
| Indivior Inc. | 4 | $97 |
| Teva Pharmaceuticals USA, Inc. | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| ABBVIE INC. | 1 | $21 |
| Braeburn Inc. | 1 | $14 |
Products named: COBENFY, ARISTADA, CAPLYTA, INGREZZA, SUBLOCADE, UZEDY, REXULTI, VRAYLAR.
Industry payments across MA — which companies pay providers there.
